Skip to main content

Table 3 PAH medication treatment patterns (12 month follow-up)

From: The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients

  PAH subjects 1(N = 425)
  n %
Discontinuation of index therapy regimen 162 38.12
Switch from index therapy regimen2 23 14.20
Augmentation to index therapy regimen 47 11.06
Maintenance of index therapy regimen 224 52.71
Medication Possession Ratio (MPR) n mean
 Bosentan 177 0.94
 Ambrisentan 29 0.94
 Iloprost 4 0.86
 Treprostinil 2 1.00
 Epoprostenol 0 -
 Tadalafil (Adcirca®) 22 0.94
 Sildenafil (Revatio®) 191 0.92
  1. 1Of the subjects in the final sample, 425 were monotherapy pharmacy users in the 30 days following the index date; these subjects were included in the analysis of follow-up treatment patterns.
  2. 2Percentage of switchers calculated out of subjects who discontinued (n = 162).